New York, NY -- (SBWIRE) -- 12/20/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Huntington Bancshares Incorporated (NASDAQ:HBAN), Oxygen Biotherapeutics, Inc (NASDAQ:OXBT), Dynavax Technologies Corporation (NASDAQ:DVAX), Banco Santander, S.A. (ADR) (NYSE:SAN)
Huntington Bancshares Incorporated (NASDAQ:HBAN) the stock opened the session at $9.50 but then moved to $9.50. At that price, the stock showed a positive performance of 9.55%. Huntington Bancshares Incorporated (Huntington) is a multi-state diversified regional bank holding company. Through its subsidiaries, including its bank subsidiary, The Huntington National Bank (the Bank), Huntington is engaged in providing full-service commercial, small business, consumer banking services, mortgage banking services, automobile financing, equipment leasing, investment management, trust services,
Will HBAN Continue To Move Higher? Find Out Here
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) opened the session at $4.35 and closed the session at $5.05. The stock showed a positive performance of 15.84% in previous trading session. Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications.
For How Long OXBT will fight for Profitability? Read This Trend Analysis report
Dynavax Technologies Corporation (NASDAQ:DVAX) opened the session at $1.83 and closed the session at $1.79. The stock showed a negative performance of -0.56% in previous trading session. The beta of the stock remained 2.75. Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company’s pipeline of product candidates includes HEPLISAV,
Why Should Investors Buy DVAX After the Recent Fall? Just Go Here and Find Out
Banco Santander, S.A. (ADR) (NYSE:SAN) the stock advanced 0.81% and finished the session at $8.69. Traded with volume of 5.98 million shares in the prior session and the average volume of the stock remained 5.57 million shares. The beta of the stock remained 1.93. Banco Santander SA is a Spain-based commercial bank. The Bank operates principally in Spain, the United Kingdom, Portugal, the Latin American countries and the United States. It operates four segments: Continental Europe, the United Kingdom, Latin America and Sovereign. Continental Europe segment covers all retail banking business, wholesale banking and asset management and insurance conducted in Europe, under such names as Santander Totta, Santander Consumer Bank and Bank Zachodni WBK, among others.
Will SAN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)